Health and Healthcare

Teva : TEVA

All Teva Articles

450 Articles

Lee Jackson | Jun 24, 2016 at 8:56 AM EDT

J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks

[cnxvideo id=”655379″ placement=”ros”]Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have…

Lee Jackson | Jun 23, 2016 at 8:25 AM EDT

Blue Chips Dominate Jefferies Value Stocks to Buy

This week's top value calls from the analysts at Jefferies focus on blue chip companies that are, for the most…

Chris Lange | Jun 21, 2016 at 10:40 AM EDT

With Acquisitions, Will Impax Become the Next Great Generic Drug Seller?

Impax Laboratories plans to take on a substantial portfolio of generic drugs in a transaction that will be immediately accretive…

Trey Thoelcke | Jun 11, 2016 at 9:20 AM EDT

3 Biotechs That Just Announced Successful Phase 2 Trials

Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.

Chris Lange | Jun 10, 2016 at 8:05 AM EDT

Major Pharma Has Short Sellers on the Run

The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | May 25, 2016 at 8:15 AM EDT

Short Sellers Take Mixed Stance on Major Pharma

The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | May 11, 2016 at 8:45 AM EDT

Major Pharma Short Interest Continues to Recede

The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical…

Paul Ausick | May 6, 2016 at 4:04 PM EDT

The 52-Week Low Club for Friday

May 6, 2016: Here are four stocks trading with heavy volume among 83 equities making new 52-week lows in Friday’s…

Jon C. Ogg | May 5, 2016 at 7:40 AM EDT

10 Stocks to Own for the Decade

24/7 Wall St. is revisiting a strategy that was first published in late 2010, and then again refreshed in 2015.…

Jon C. Ogg | May 4, 2016 at 11:25 AM EDT

Why Credit Suisse’s Neutral Rating on Teva Almost Sounds Like a Buy Rating

Credit Suisse's new Neutral rating on Teva Pharmaceutical Industries actually comes with significant upside.

Jon C. Ogg | May 4, 2016 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: Anadarko, Dollar General, Encana, FedEx, Teva, UBS and Many More

The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Anadarko Petroleum, Dollar General, Encana, FedEx, Teva Pharmaceutical…

Chris Lange | Apr 27, 2016 at 9:15 AM EDT

Major Pharma Short Interest Remains Mixed, With 1 Massive Drop

The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Sam Stebbins | Apr 26, 2016 at 6:57 AM EDT

The World’s 15 Top Selling Drugs

Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also…

Chris Lange | Apr 12, 2016 at 9:50 AM EDT

Short Sellers Become More Selective in Major Pharma

The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Paul Ausick | Mar 18, 2016 at 4:04 PM EDT

The 52-Week Low Club for Friday

March 18, 2016: Here are four stocks trading with heavy volume among 25 equities making new 52-week lows in Friday’s session.…

1 … 16 17 18 19 20 … 30

Teva : TEVA

All Teva Articles

J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks

Blue Chips Dominate Jefferies Value Stocks to Buy

With Acquisitions, Will Impax Become the Next Great Generic Drug Seller?

3 Biotechs That Just Announced Successful Phase 2 Trials

Major Pharma Has Short Sellers on the Run

Short Sellers Take Mixed Stance on Major Pharma

Major Pharma Short Interest Continues to Recede

The 52-Week Low Club for Friday

10 Stocks to Own for the Decade

Why Credit Suisse’s Neutral Rating on Teva Almost Sounds Like a Buy Rating

Top Analyst Upgrades and Downgrades: Anadarko, Dollar General, Encana, FedEx, Teva, UBS and Many More

Major Pharma Short Interest Remains Mixed, With 1 Massive Drop

The World’s 15 Top Selling Drugs

Short Sellers Become More Selective in Major Pharma

The 52-Week Low Club for Friday

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Teva : TEVA

All Teva Articles

J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks

Blue Chips Dominate Jefferies Value Stocks to Buy

With Acquisitions, Will Impax Become the Next Great Generic Drug Seller?

3 Biotechs That Just Announced Successful Phase 2 Trials

Major Pharma Has Short Sellers on the Run

Short Sellers Take Mixed Stance on Major Pharma

Major Pharma Short Interest Continues to Recede

The 52-Week Low Club for Friday

10 Stocks to Own for the Decade

Why Credit Suisse’s Neutral Rating on Teva Almost Sounds Like a Buy Rating

Top Analyst Upgrades and Downgrades: Anadarko, Dollar General, Encana, FedEx, Teva, UBS and Many More

Major Pharma Short Interest Remains Mixed, With 1 Massive Drop

The World’s 15 Top Selling Drugs

Short Sellers Become More Selective in Major Pharma

The 52-Week Low Club for Friday

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do